CSL Limited: Iron Deficiencies trials

The registry lists 20 Iron Deficiencies studies with CSL Limited as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 2 1Phase 3 9Phase 4 4No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency AnaemiaCompletedNCT03591406Phase 3Results posted
• Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron DeficiencyCompletedNCT02937454Phase 4Results posted
• Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT00994318Phase 3Results posted
• Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital EnvironmentCompletedNCT05514951Not applicable
• Study of the Prevalence of Iron Deficiency in Patients With Scheduled Major Surgery (CARENFER PBM)Status unknownNCT04800042Not applicable
• Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel DiseaseStatus unknownNCT04123990Not applicable
• Study of the Prevalence of Iron Deficiency in Patients With Chronic Renal Failure But Non-Dialysis (CARENFER IRC-ND)Status unknownNCT04123145Not applicable
• Prevalence Study of Iron Deficiency in Patients With CancerStatus unknownNCT03924271Not applicable
• Study of the Prevalence of Iron Deficiency in Patients With Heart FailureStatus unknownNCT03924258Not applicable
• A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron DeficiencyCompletedNCT01453608Phase 4
• Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart FailureCompletedNCT01394562Phase 3
• Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant WomenCompletedNCT01131624Phase 3
• Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing AgeCompletedNCT01110356Phase 4
• Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing ChemotherapyCompletedNCT01101399Phase 3
• Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01100879Phase 4
• Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)TerminatedNCT00882414Phase 2
• EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart FailureTerminatedNCT00821717Phase 3
• FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-CORCompletedNCT00810030Phase 3
• Maintenance Treatment of Iron Deficiency in IBD PatientsCompletedNCT00810004Phase 3
• Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)CompletedNCT00520780Phase 3